Researchers find potential path to a broadly protective COVID-19 vaccine using T cells
Using a method developed for HIV, researchers have identified stable T cell vaccine targets in SARS-CoV-2.
Anthony Iafrate, MD, PhD
Anthony Iafrate, MD, PhD
Austin L. Vickery, Jr. Professor of Pathology
Vice Chair of Pathology for Academic Affairs
Pathologist in Pathology, Massachusetts General Hospital
Vice Chair of Pathology for Academic Affairs
Pathologist in Pathology, Massachusetts General Hospital
About Anthony Iafrate, MD, PhD
Dr. Iafrate is a Professor of Pathology at Harvard Medical School, former Director of the Center for Integrated Diagnostics (CID), a clinical laboratory for molecular diagnostics at Massachusetts General Hospital and is currently the Vice Chair of Academic Affairs at the Massachusetts General Hospital (MGH). Dr. Iafrate received his MD/PhD dual degree from the State University of New York at Stony Brook in 2000 and was trained in anatomic and molecular genetic pathology at Brigham and Women’s Hospital. Dr. Iafrate is a board-certified Pathologist and has been on staff at MGH since 2005. The CID provides rapid personalized genomic testing to help inform cancer treatment decisions for patients. His research is focused on lung and brain tumors, where he has been closely involved in the clinical development of crizotinib and companion diagnostics in ALK- and ROS1 positive lung cancers. His lab has developed several technologies for sequencing tumors, including SNaPshot and the next-generation sequencing-based Anchored Multiplex PCR, both techniques have been widely used in the molecular diagnostics community.
Departments, Centers, & Programs:
Clinical Interests:
- Molecular pathology
Treats:
- Adult
Locations
Pathology Associates
55 Fruit Street
Boston, MA 02114-2696
Fax: 617-726-7474
Medical Education
- MD, State University of New York, Stony Brook School of Medicine And Biomedical Sciences
- M.D.; Ph.D., Stony Brook Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Brigham and Women's Hospital
American Board Certifications
- Molecular Genetic Pathology, American Board of Medical Genetics
- Anatomic Pathology, American Board of Pathology
- Anatomic Pathology, American Board of Pathology
Accepted Insurance Plans
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- MassHealth
- Medicare
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Senior Whole Health
- TriCare
- Tufts Health Plan
- Unicare
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Research
Research in the Iafrate laboratory focuses on bringing new genetic technologies to cancer diagnostics and their application to the practice of pathology. Initially research focused on lung cancer, but our approach is expanding to all malignancies. For more information about research concepts, co-authors, and to see a timeline, visit Dr. Iafrate's profile at the Harvard Clinical and Translational Science Center.
Publications
-
View my most recent publications at PubMed
- Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival. Batal I, De Serres SA, Safa K, Bijol V, Uneo T, Onozato ML, Iafrate AJ, Herter JM, Lichtman AH, Mayadas TN, Guleria I, Rennke HG, Najafian N, Chandraker A. J Am Soc Nephrol. 2015 Apr 8. Epub ahead of print]
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, J?nne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA. Nat Commun. 2015 Mar 11;6:6377.
- Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience. Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Chen H, Fujimoto J, Kugler K, Franklin WA, Iafrate AJ, Ladanyi M, Kris MG, Johnson BE, Bunn PA, Minna JD, Kwiatkowski DJ; LCMC Investigators. J Thorac Oncol. 2015 May;10(5):768-77.